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Postoperative pulmonary complications (PPCs) significantly impact surgical outcome. We investigated 
the predictive ability of controlling nutritional status (conUt) for ppc after lung resection in patients 
with non-small cell lung cancer (NSCLC). We retrospectively reviewed data of 922 patients with NSCLC 
who underwent complete resection from January 2016–December 2017. We analyzed the frequency 
and characteristics of ppcs and compared receiver operating characteristic (Roc) curves of various 
prognostic models to predict PPCs. A CONUT score higher than 1 was considered as a high CONUT 
score. Total incidence of PPCs was 8.6% (n = 79). The proportion of pneumonia was significantly larger 
in the high conUt group (P < 0.05). The CONUT consistently had a higher area under curve (AUC) 
value (0.64) than other prognostic models (prognostic nutritional index (PNI): AUC = 0.61, Glasgow 
prognostic score (GPS): AUC = 0.57, and assessment of respiratory risk in surgical patients in Catalonia 
(ARISCAT): AUC = 0.54). Multivariate analysis identified underweight [Odds ratio (OR) = 4.57, P = 0.002] 
and high CONUT score (OR = 1.91, P = 0.009) as independent PPCs prognostic factors. One-year 
mortality rate for high CONUT score was significantly higher (hazard ratio = 7.97; 95% confidence 
interval, 1.78–35.59). Preoperative CONUT score is an independent predictor of PPCs and 1-year 
mortality in patients with resectable NSCLC.
Postoperative complication (PPC) is critically important for patient outcomes, and is associated with mortality, 
morbidity, and length of stay in both thoracic and non-thoracic surgical  patients1. Although the definition of 
PPCs varies in the literature, it generally includes prolonged air leak, pneumothorax, atelectasis, pleural effusion, 
respiratory infections, broncho-pleural fistula, and acute respiratory distress syndrome (ARDS)2.
In patients undergoing thoracic surgery in particular, the incidence of PPCs is reported to be between 3 and 
49%, with mortality ranges ranging 2–12%3. Therefore, careful preoperative evaluation is needed to predict PPCs, 
and this is a common concern among thoracic surgeons, pulmonologists, and anesthesiologists. Various PPCs 
prediction models have been previously developed; these include the assessment of respiratory risk in surgical 
patients in Catalonia (ARISCAT) model, Gupta risk calculators, and the respiratory failure risk index suggested 
by Arozullah et al.2,4–6. However, these models require diverse preoperative parameters, which bring question-
able clinical usefulness of those. Moreover, detailed nutritional status is not reflected in any of these models.
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Recently, a number of studies have reported that the presence of a systemic inflammatory response and 
malnutrition is associated with poor prognosis in various malignancies. It has also been shown that systemic 
inflammation-based prognostic scores, such as the prognostic nutritional index (PNI) and Glasgow prognostic 
score (GPS), have independent prognostic value regardless of tumor stage in various malignancies, including 
non-small cell lung cancer (NSCLC)7–11.
Similar to these inflammation-based prognostic scores, the controlling nutritional status (CONUT) score, 
which is calculated using serum albumin, total cholesterol, and total peripheral lymphocyte count, was sug-
gested as a screening tool for early detection of under-nutrition12. The CONUT scoring tool is low-cost and 
simple to use. Previous studies have demonstrated its relationship with long-term clinical outcomes in various 
 malignancies13–18.
However, the clinical significance of the CONUT score for predicting postoperative outcomes in patients with 
operable NSCLC who have undergone lung resection is still unknown. Therefore, this study aimed to investigate 
whether the CONUT score can serve as an independent predictor of PPCs in patients with completely resected 
NSCLC.
Materials and methods
Study population and data collection. We conducted this retrospective observational study using the 
data of 934 patients who underwent lung resection surgery with curative intent for resectable NSCLC at Sev-
erance Hospital (Seoul, South Korea) between January 2016 and December 2017. Of these, 12 patients were 
excluded owing to unmeasured laboratory data, surgically confirmed advanced stage (M1), or other insuffi-
cient data (Supplementary Fig. 1). Preoperative and postoperative clinical data were collected from the medical 
records and database. Laboratory data were obtained within 1 week before the surgery. The Institutional Review 
Board of Severance Hospital approved the study protocol and waived the informed consent from the patients 
due to the retrospective nature of the study (IRB No.: 4-2018-0922).
Study design. Preoperative and postoperative clinical characteristics, PPCs, and 1-year overall mortality 
were compared between high and low CONUT groups. The ability of the CONUT score to predict major PPCs 
was analyzed and compared with that of the PNI, GPS and ARISCAT.
Definitions. PPCs were defined as any one or more of the following complications: prolonged air leak, pneu-
monia, pneumothorax, chylothorax, ARDS, bleeding, bronchopulmonary fistula, empyema, atelectasis, and 
pleural  effusion1. Bleeding complication was defined as reoperation or transfusion of three or more red blood 
cell packs to control massive hemoptysis or continuous bleeding through the chest tube. Respiratory infection 
within 1 month before surgery was defined as recent respiratory infection. Low preoperative  SpO2 was defined as 
below 96% and anemia was defined as hemoglobin level below 10.0 g/dL. Obesity and underweight were defined 
as body mass index (BMI) ≥ 25 kg/m2 and BMI < 18.5 kg/  m2, respectively.
Table 1 shows inflammation-based prognostic scores and postoperative pulmonary risk scoring system, 
which were used in our study. The CONUT score (range, 0–12) was assessed, using serum albumin level, total 
lymphocyte count, and total cholesterol level. The ARISCAT risk score was calculated as the sum of seven 
patient- or surgery-related risk factor scores (range, 0–123). PNI was calculated using serum albumin level and 
total lymphocyte count and was scored as 0 or 1. GPS was calculated using serum C-reactive protein and albumin 
levels and was also scored as 0 or 1.
The optimal cut-off values for CONUT, PNI, GPS and ARISCAT scores were determined by receiver operating 
characteristic (ROC) curves. The best cut-off points for CONUT, PNI, GPS, ARISCAT score were 1.0, 43.4, 1.0, 
and 49.0, respectively, corresponding to maximum joint sensitivity and specificity. Distribution of study popula-
tion depending on CONUT scores and the comparison of ROC curves between the different cut-off values of 
CONUT are described in Fig. 1A and B, respectively. Those with a CONUT score > 1.0 were categorized into the 
high CONUT group while those with score of ≤ 1.0 were categorized into the low CONUT group.
Statistical analysis. We conducted statistical comparison using SPSS Statistics Version 23 (IBM Co., 
Armonk, NY, USA). We conducted univariate analyses with χ2 test for categorical variables and Student’s t-test 
for continuous variables. Significant prognostic factors for PPCs in univariate analyses were selected for multi-
variate logistic analysis. We evaluated the ability of CONUT, PNI, GPS, and ARISCAT scores to predict PPCs 
using the ROC curve. We compared 1-year overall mortality between high and low CONUT groups through the 
Kaplan–Meier method and conducted Cox regression analyses to determine independent prognostic factors. A 
value of P < 0.05 was considered to be statistically significant.
Ethical standards. This article does not contain any studies with human or animal subjects performed by 
any of the authors.
Results
Baseline characteristics. A total of 922 patients were eligible to be included in this study. Patient charac-
teristics and clinic-pathologic features are presented in Tables 2 and 3; the mean patient age was 64.2 years and 
522 (56.6%) of the patients were men. Mean follow-up duration was 20.4 months. The majority of patients were 
diagnosed with stage I NSCLC (n = 665, 72.1%), and the most common histologic type was adenocarcinoma 
(n = 715, 77.5%). The most common type of operation was lobectomy (80.8%), followed by segmentectomy 
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(6.9%), wedge resection (5.6%), bilobectomy (3.5%), and pneumonectomy (3.2%). Eighty-five percent of the 
patients underwent video-assisted thoracoscopic surgery.
Of the 922 patients, 370 (40.1%) and 552 (59.9%) patients were categorized into the high and low CONUT 
group, respectively. Compared to the low CONUT group, the high CONUT group had an older mean age and a 
larger proportion of patients who were men, smokers, and had various comorbidities, including hypertension, 
diabetes, chronic kidney disease, and chronic obstructive pulmonary disease (COPD). Among the pulmonary 
function parameters, forced expiratory volume in 1 s  (FEV1) and diffusing capacity of the lungs for carbon mon-
oxide (DLco) were lower in the high CONUT group than in the low CONUT group (Table 2). Pneumonectomy 
and bilobectomy were more frequently performed in the high CONUT group than in the low CONUT group. 
The low CONUT group had a higher proportion of patients with stage 1 NSCLC than the high CONUT group. 
The PNI, GPS, and ARISCAT scores were all significantly higher in the high CONUT group than in the low 
CONUT group (Table 3).
Postoperative pulmonary complications in the high and low CONUT groups. PPCs between the 
high and low CONUT groups are compared in Table 4. Seventy-nine patients (8.6%) developed a total of 106 
PPCs. Prolonged air leak (44.3%) was the most common PPC, followed by pneumonia (32.9%) and pneumo-
thorax (11.3%). A higher frequency of total PPCs (12.7% vs. 5.8%, P < 0.001) was observed in the high CONUT 
group. Among all PPCs, prolonged air leak (5.4% vs. 2.7%, P = 0.036), pneumonia (4.6% vs. 1.6%, P < 0.008), and 
postoperative bleeding (1.4% vs. 0.2%, P = 0.041) were more frequently observed in the high CONUT group than 
in the low CONUT group.
Comparison between preoperative risk assessment scores for PPC predictability. The ability 
of the four preoperative risk assessment scores to predict PPCs is shown in Fig. 2. The area under the curve 
Table 1.  Inflammation-based prognostic scores and postoperative pulmonary risk scoring system. *ARISCAT 
risk class is determined by sum of each score of risk factors. CONUT controlling nutritional status, PNI 
Prognostic nutritional index, GPS Glasgow prognostic score, ARISCAT The Assess Respiratory Risk in Surgical 
Patients in Catalonia Risk Index: Independent Predictors of Postoperative Pulmonary Complications, SpO2 
oxygen saturation, Hb hemoglobin.
Parameters Score
CONUT
1. Albumin  ≥ 3.50 (0) 3.00–3.49 (2) 2.50–2.99 (4)  < 2.50 (6)
2. Total lymphocyte count, 
/mL  > 1,600 (0) 1,200–1599 (1) 800–1,199 (2)  < 800 (3)
3. Total cholesterol, mg/dL  > 180 (0) 140–180 (1) 100–139 (2)  < 100 (3)
Assessment (1 + 2 + 3) Normal (0–1) Mild (2–4) Moderate (5–8) Severe (9–12)
PNI
Calculation Score
Albumin (g/L) + 5 × total 
lymphocyte count/mL ≥ 45 0
Albumin (g/L) + 5 × total 
lymphocyte count/mL < 45 1
GPS
Calculation Score
C-reactive protein ≤ 10 mg/L 
and albumin ≥ 35 g/L 0
C-reactive protein ≤ 10 mg/L 
and albumin < 35 g/L 1
C-reactive protein > 10 mg/L 
and albumin ≥ 35 g/L 1
C-reactive protein > 10 mg/L 
and albumin < 35 g/L 2
ARISCAT*
Risk factors Risk score
Age, year  ≤ 50 (0) 51–80 (3) > 80 (16)
Preoperative  SpO2, %  ≥ 96 (0) 91–95 (8) ≤ 90 (24)
Respiratory infection in last 
month No (0) – Yes (17)
Preoperative Hb ≤ 10 g/dL No (0) – Yes (11)
Surgical incision site Peripheral (0) Upper abdominal (15) Intrathoracic (24)
Duration of surgery, hours < 2 (0) 2–3 (16) > 3 (23)
Emergency procedure No (0) – Yes (8)
Risk class* No. of points in risk score (pulmonary complication rate)
Low < 26 (1.6%)
Intermediate 26–44 (13.3%)
High < 44 (42.1%)
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Figure 1.  Frequency distribution of CONUT scores and comparison of the area under the ROC curve for PPCs 
predictability of the CONUT depending on different cut-off values. (A) Distribution of the study population 
depending on CONUT score. Approximately half of the study population had a CONUT score of 0 or 1 (452 
of 922, 49.0%). (B) ROC curves for PPCs according to the various cut-off values of CONUT. The AUCs were 
0.594 (CONUT > 0), 0.642 (CONUT > 1), 0.601 (CONUT > 2), and 0.591 (CONUT > 3). AUC area under curve, 
CONUT controlling nutritional status, PPCs postoperative pulmonary complications, ROC receiver operating 
characteristic, CI confidence interval.
Table 2.  Patient characteristics [Significant differences (p < 0.05)]. CONUT controlling nutritional status, 
COPD chronic obstructive pulmonary disease, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 







(n = 552) p-value
Age, > 65 years 485 (52.6) 235 (63.5) 250 (45.3) < 0.001
Sex, man 522 (56.6) 235 (63.5) 287 (52.0) < 0.001
Body mass index 24.1 ± 3.1 22.6 ± 1.7 24.3 ± 2.2 0.713
 Obese (> 25 kg/m2) 337 (36.6) 121 (32.7) 216 (39.1) 0.051
 Underweight (< 18.5 kg/m2) 23 (2.5) 13 (3.5) 10 (1.8) 0.131
Ever smoker 392 (42.5) 195 (52.7) 197 (35.5) < 0.001
Comorbidities
Hypertension 412 (44.7) 206 (55.7) 206 (37.3) < 0.001
Diabetes 163 (17.7) 103 (27.8) 60 (10.9) < 0.001
Chronic kidney disease 94 (10.2) 56 (15.1) 38 (6.9) < 0.001
COPD 93 (10.1) 51 (13.8) 42 (7.6) 0.003
Preoperative findings
Respiratory infection(within 1 month) 370 (40.1) 12 (3.2) 4 (0.7) 0.008
Hypoxemia  (SpO2 < 96%) 15 (1.6) 10 (2.7) 5 (0.9) 0.059
Laboratory tests
White blood cell count, /μL 6,633 ± 2,616 6,770 ± 3,535 6,541 ± 1745 < 0.001
Hemoglobin, g/dL 13.2 ± 1.4 12,8 ± 1.4 13.5 ± 1.3 0.128
Lymphocyte count, /μL 2069 ± 701 1816 ± 741 2,239 ± 617 < 0.001
Albumin, g/dL 3.7 ± 0.4 3.4 ± 0.5 3.8 ± 0.2 < 0.001
Cholesterol, mg/dL 175 ± 39 150 ± 37 192 ± 31 < 0.001
C-reactive protein, mg/dL 48.7 ± 38.2 52.8 ± 45.1 40.8 ± 31.9 < 0.001
Pulmonary function
FEV1, L 2.3 ± 0.6 2.1 ± 0.5 2.3 ± 0.7 0.015
FEV1, % 99.1 ± 19.0 83.9 ± 15.2 94.3 ± 13.9 0.112
FEV1/FVC, % 0.7 ± 9.5 68.1 ± 11.6 65.9 ± 10.2 0.034
DLco, % 95.2 ± 18.3 83.7 ± 21.5 87.1 ± 12.2 0.008
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(AUC) of CONUT, PNI, GPS, and ARISCAT was 0.64 (95% CI 0.63–0.69), 0.61 (95% CI 0.58–0.65), 0.57 (95% 
CI 0.54–0.60) and 0.54 (95% CI 0.51–0.57), respectively. The AUC of CONUT was significantly higher than that 
of GPS (P = 0.01) and ARISCAT (P < 0.01), while AUC of CONUT was non-significantly higher than that of PNI 
(P = 0.397).
According to the multivariate analysis of the risk factors for PPCs, high CONUT score had an odds ratio 
of 1.91 (95% CI, 1.17–3.10). Underweight was also an independent risk factor for PPCs (OR = 4.57; 95% CI, 
1.76–11.83) (Table 5).
Relationship between preoperative nutritional status and postoperative mortality. We ana-
lyzed the relationship between CONUT status and 1-year mortality; we found that 1-year mortality was higher 
in the high CONUT group compared to the low CONUT group (15 of 555 [2.7%] vs. 4 of 367 [0.1%], P < 0.001). 
Kaplan–Meier analysis revealed a significantly higher 1-year mortality rate in the high CONUT group in both 
the entire study population (P < 0.001; Fig. 3A) and among the 79 patients with PPCs (P = 0.028; Fig. 3B). Accord-
ing to the multivariate Cox regression analysis for 1-year mortality, high CONUT score had a hazard ratio of 
6.62 (95% CI 1.43–30.66) (Table 6). Man (HR = 6.47; 95% CI 1.09–38.24), advanced pathologic stage (stage II-
Table 3.  Comparison of clinico-pathological features between high and low CONUT groups [Significant 
differences (p < 0.05)]. CONUT controlling nutritional status, PNI prognostic nutritional index, GPS Glasgow 
prognostic score, ARISCAT assessment of respiratory risk in surgical patients in Catalonia, VATS video-
assisted thoracoscopic surgery. † In the II/III group, 144 (15.6%) and 13 (12.3%) patients were categorized as 
stage II and III, respectively. **In the II/III group, 85 (23.0%) and 59 (14.9%) patients were categorized as stage 








(n = 552) P-value
Types of operation
Pneumonectomy 29 (3.2) 17 (4.6) 12 (2.2) 0.039
Lobectomy 745 (80.8) 291 (78.6) 454 (82.3) 0.174
Bilobectomy 32 (3.5) 19 (5.1) 13 (2.4) 0.024
Segmentectomy 64 (6.9) 25 (6.8) 39 (7.0) 0.857
Wedge resection 52 (5.6) 18 (4.9) 34 (6.1) 0.404
VATS 789 (85.6) 289 (78.1) 500 (90.6) < 0.001
Postoperative findings
p-stage < 0.001
 I 665 (72.1) 230 (62.1) 435 (78.8)
 II/III 257 (27.8)† 140 (37.8)** 117 (62.1)††
Adenocarcinoma 715 (77.5) 248 (67.0) 467 (84.6) < 0.001
PPC predictors
CONUT score 1.6 ± 1.8 3.4 ± 1.7 0.5 ± 0.5
PNI 42.6 ± 5.7 46.4 ± 5.9 40.1 ± 4.0 < 0.001
GPS 1.0 ± 0.6 1.4 ± 0.6 0.8 ± 0.4 < 0.001
ARISCAT 44.1 ± 3.9 45.0 ± 4.8 43.5 ± 3.0 < 0.001
Table 4.  Postoperative pulmonary complication between high and low CONUT groups [Significant 







(n = 552) p-value
Total 79 (8.6) 47 (12.7) 32 (5.8)  < 0.001
Prolonged air leak 35 (3.8) 20 (5.4) 15 (2.7) 0.036
Pneumonia 26 (2.8) 17 (4.6) 9 (1.6) 0.008
Pneumothorax 9 (1.0) 6 (1.6) 3 (0.5) 0.103
Chylothorax 8 (0.9) 4 (1.1) 4 (0.7) 0.567
ARDS 7 (0.8) 5 (1.4) 2 (0.4) 0.090
Bleeding 6 (0.7) 5 (1.4) 1 (0.2) 0.030
Bronchopulmonary fistula 5 (0.5) 3 (0.8) 2 (0.4) 0.183
Empyema 4 (0.4) 1 (0.3) 3 (0.5) 0.536
Atelectasis 3 (0.3) 2 (0.5) 1 (0.2) 0.348
Pleural effusion 3 (0.3) 2 (0.5) 1 (0.2) 0.348
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III) (HR = 6.49; 95% CI 1.94–21.71), and recent respiratory infection (HR = 13.11; 95% CI 2.71–63.45) were also 
independent risk factors for 1-year mortality.
Discussion
The results of this study suggest that a high CONUT score is associated with occurrence of PPCs after lung 
resection in patients with NSCLC. Moreover, in these patients, a high CONUT score is a significant prognostic 
factor for 1-year mortality. The CONUT score has been previously reported as a useful prognostic predictor for 
various malignant tumors, but data on its use in case of completely resected NSCLC are  limited13–18. Thus, this 
is the first study to investigate the usefulness of the CONUT score for predicting PPCs and 1-year mortality in 
patients with completely resected NSCLC. Among the patients who underwent lung resection, 8.6% developed 
PPCs; this is a much lower rate than previously reported in patients after thoracic surgery (19–59%)19. Stephan 
et al. reported a PPC rate of 25% following lung resection performed by open  thoracotomy3. In our study, 85% of 
patients underwent video-assisted thoracoscopic surgery, which might have resulted in better clinical outcomes. 
We found that prolonged air leak was the most frequent PPC, followed by pneumonia; this was in accordance 
with the results previously reported by Stephan et al.3
Figure 2.  Comparison of the area under the ROC curve for PPCs predictability of the CONUT and 
inflammation-based prognostic scores/ARISCAT score. The ability of various preoperative risk assessment 
scores to predict PPCs was compared using ROC curve. The AUC of the CONUT, PNI, GPS, and ARISCAT 
were 0.64 (95% CI 0.63–0.69), 0.61 (95% CI 0.58–0.65), 0.57 (95% CI; 0.54–0.60) and 0.54 (95% CI 0.51–0.57), 
respectively. The AUC of the CONUT was significantly higher than that of the GPS (P = 0.01) and the ARISCAT 
(P < 0.01). ARISCAT assessment of respiratory risk in surgical patients in Catalonia, AUC are under curve, 
CONUT controlling nutritional status, GPS Glasgow prognostic score, PNI prognostic nutritional index, PPCs 
postoperative pulmonary complications, ROC receiver operating characteristic, CI confidence interval.
Table 5.  Multivariate analyses of risk factors for postoperative pulmonary complications [Significant 
differences (p < 0.05)]. CI confidence interval, CONUT controlling nutritional status, HR hazard ratio, OR odds 
ratio, PPC postoperative pulmonary complication(s).
Variable
Univariate analysis Multivariate analysis
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Age > 65 years 0.71 (0.45–1.14) 0.197 – –
Sex, man 2.65 (1.55–4.51) < 0.001 1.90 (0.93–3.89) 0.077
Underweight (BMI < 18.5 kg/m2) 6.12 (2.51–14.93) < 0.001 4.57 (1.76–11.83) 0.002
Ever smoker 2.43 (1.51–3.91) < 0.001 1.44 (0.76–2.72) 0.259
Recent respiratory infection (within 1 month) 2.48 (0.69–8.90) 0.155 – –
Preoperative hypoxemia  (SpO2 < 96%) 1.63 (0.36–7.37) 0.379 – –
Preoperative anemia (Hb ≤ 10 g/dL) 0.74 (0.09–5.76) 1.000 – –
p-Stage II/III vs. I 1.53 (0.94–2.50) 0.083 – –
High CONUT (> 1) 2.42 (1.51–3.87) < 0.001 1.91 (1.17–3.10) 0.009
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However, the 1-year mortality rate in our study (2.0%) was lower than that reported in previous studies. Short-
term prognosis of NSCLC patients that underwent lung resection varied depending on the follow-up period, 
type of surgical procedure, and characteristics of study populations. Veen et al. previously described operative 
mortality, which was defined as death at any time during initial hospitalization or within 30 days after surgery, 
and was 2.1% among patients who underwent pulmonary surgery due to  NSCLC20. However, another study by 
Ren et al., which showed the short-term effects of thoracoscopic segmentectomy and thoracoscopic lobectomy 
on solitary pulmonary nodules and early-stage lung cancer, demonstrated no death among 82 patients within 
the 1-year follow-up  period21. In contrast, Eguchi et al. reported a 1-year mortality rate of 4.1% in stage I non-
small-cell lung cancer patients. The most common cause of death was non-cancer specific (50%), followed by lung 
cancer specific (27.8%), and other cancer specific (27.8%). Moreover, non-cancer specific mortality represents 
a significant competing event for lung cancer-specific mortality, with an increasing impact as age  increases22. 
These studies suggest that the composition of the study population could affect short-term mortality rates. In 
our study, more than two-thirds of the study population had stage I cancer, and relatively young patients below 
65 years of age accounted for more than half of the study population. This could be a possible reason why our 
study showed a lower short-term mortality rate.
Precise quantitative prediction of PPCs risk factors is essential for surgeons and anesthesiologists to prepare 
safe patient management plans. For decades, various risk factors have been identified to aid in predicting PPCs, 
Figure 3.  Kaplan–Meier survival curves according to CONUT status of (A) all subjects, (B) subjects with PPCs. 
One-year mortality was higher in the high CONUT group than in the low CONUT group, both in whole study 
population (P < 0.001; A) and among the 79 patients with PPCs (P = 0.028; B). CONUT controlling nutritional 
status, PPCs postoperative pulmonary complications
Table 6.  Cox regression analyses of risk factors for 1-year mortality [Significant differences (p < 0.05)]. CI 
confidence interval, CONUT controlling nutritional status, HR hazard ratio, OR odds ratio, PPC postoperative 
pulmonary complication(s).
Variable
Univariate analysis Multivariate analysis
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age > 65 years 2.21 (0.77–6.33) 0.129 – –
Sex, man 5.96 (1.35–26.23) 0.007 6.47 (1.09–38.24) 0.039
Underweight (BMI < 18.5 kg/m2) 0.97 (0.96–0.98) 0.513 – –
Ever smoker 2.76 (1.03–7.44) 0.036 0.49 (0.14–1.68) 0.260
Recent respiratory infection (within 1 month) 14.52 (3.72–56.68) < 0.001 13.11 (2.71–63.45) 0.001
Preoperative hypoxemia  (SpO2 < 96%) 4.23 (0.52–34.35) 0.141 – –
Preoperative anemia (Hb ≤ 10 g/dL) 3.92 (0.48–31.7) 0.166 – –
p-Stage II/III vs. I 9.06 (2.92–28.0) < 0.001 6.49 (1.94–21.71) 0.002
High CONUT (> 1) 11.65 (2.65–51.28) < 0.001 6.62 (1.43–30.66) 0.016
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and several risk scoring systems have been developed to comprehensively evaluate  PPCs2,19,23. Among these, the 
ARISCAT score is simple to use in clinical practice and has been prospectively validated for use in estimating 
 PPCs24. However, in this study, most of the study population was elderly patients with NSCLC who underwent 
lung resection, and they were thus classified in the same high-risk group. Therefore, a more strategic tool is 
needed to classify patients in a similar risk category who are more likely to develop PPCs. For this purpose, the 
CONUT score showed superiority in predicting PPCs, as compared with the other inflammatory prognostic 
marker (GPS) or preoperative risk scoring system (ARISCAT score); AUC analysis showed that the CONUT 
score was significantly superior to the GPS and the ARISCAT score for predicting PPCs. However, non-significant 
higher AUC was observed for CONUT compared to PNI, which could be attributable to common components 
such as albumin level and total lymphocyte counts included in both the tools.
The CONUT score is based on immune-nutritional parameters composed of three key laboratory findings: 
serum albumin concentration, total lymphocyte count, and serum cholesterol  level13.
Serum albumin is widely used to assess nutritional status, as well as current status of systemic illness and 
 inflammation25, although hypoalbuminemia is associated with an impaired immune response through mac-
rophage activation, there is evidence that shows that hypoalbuminemia is also associated with older age, inde-
pendent of elevated C-reactive protein (CRP) levels. Hypoalbuminemia may have additional prognostic value 
besides its relationship with systemic inflammatory  response26,27. Accordingly, perioperative nutritional support 
is considered as an effective strategy to improve surgical outcomes. Even though routine supplemental admin-
istration of albumin showed no apparent advantages in the treatment of patients in the surgical ICU, findings 
regarding the effect of pre- or postoperative nutritional intervention, regardless of the route and formula used, 
were  promising28–30. In addition, the study by Kabata et al. demonstrated that the preoperative nutritional support 
could be helpful to maintain proper nutritional status and to reduce the number and severity of postoperative 
complications even in non-malnourished  patients31. The association between low serum albumin and risk of 
PPCs is well-supported in the  literature2,6,23,32. Lymphocytopenia is also related with malnutrition and suppres-
sion of cellular immunity. Impaired cell-mediated immunity leads to a weakened antibacterial cellular immune 
response, contributing to an increased chance of bacterial  infection33,34. Moreover, the immune response to 
tumors is lymphocyte-dependent, and as a result, a low count can be a predictor of poor survival. Regarding the 
role of serum cholesterol levels in the CONUT score, hypocholesterolemia is more significantly associated with 
fewer circulating lymphocytes, total T cells, and CD8+ cells than is hypercholesterolemia. Moreover, cholesterol 
increases the antigen-presenting function of  monocytes35. Therefore, a low serum total cholesterol level may 
contribute to a poorer prognosis by affecting intracellular signaling and impairing the immune system against 
infection, wound healing, or tumor spread.
The association between chronic inflammation and the life-cycle of tumor cells (cellular transformation, 
survival, proliferation, invasion, and metastasis) is well known, and suggests that inflammatory markers could 
be prognostic factors in  malignancies36,37. The CONUT score was previously reported to be an independent 
predictor of overall survival and relapse-free survival in patients with resectable thoracic esophageal squamous 
cell carcinoma and in those who undergo curative hepatectomy for hepatocellular  carcinoma13,18. In patients 
with colorectal cancer, preoperative CONUT scores predicted survival and postoperative severe  complications14. 
Previous studies have also revealed the prognostic predictability of CONUT score for patients with NSCLC: the 
CONUT score was an independent prognostic factor for disease-free and overall survival in patients with lung 
adenocarcinoma with obstructive lung  disease38. However, the CONUT score was not found to be a significant 
predictive or prognostic factor for the surgical outcomes of elderly patients with  NSCLC39. Our study demon-
strated the usefulness of the CONUT score in predicting both PPCs and 1-year mortality in patients with NSCLC 
undergoing curative resection; these results provide important support for the use of the CONUT score in this 
patient population.
However, unlike CONUT, GPS and PNI are composed of two variables and are relatively easy to calculate. 
To measure GPS, albumin level and CRP level are needed. Although CRP level is well-correlated with systemic 
inflammation and could be used to detect SIRS progression, there could be false positive results in the early-
phase of infection or in immunocompromised  hosts40,41. In case of PNI, albumin and total cholesterol are used 
as variables to measure similar to the CONUT score. This could be why the AUCs of CONUT and PNI showed 
similar results. However, the CONUT score, which is different from PNI, includes total cholesterol as a vari-
able. As noted above, hypocholesterolemia is known to reflect malnutrition and autoimmune disease in cancer 
patients. Hence, additional research including advanced NSCLC cases is needed to compare AUCs in terms of 
PPC predictability and survival rate.
The strength of our study is that the CONUT score is an easily available and cost-effective biomarker which 
can be combined with preexisting prognostic parameters, thus assisting decision making based on its prognostic 
value. In addition, immune-nutritional deficiency is a modifiable factor with promising data on a targeted pre-
operative nutritional supplementation that may decrease morbidity and improve survival of cancer  patients42–44.
However, a few limitations of this study should be considered. First, this was a single-center study with a 
relatively small sample size compared to other multi-center studies. However, compared to previous studies on 
the CONUT score, the sample size of this study is relatively large, and comprises patients across 2 years in a single 
center. Moreover, a single-center study would represent a limited number of surgeons, which lessens the variation 
in medical management and surgical techniques. Second, this study is likely to have selection and analytical biases 
due to the retrospective design. However, of the 934 patients who underwent lung resection surgery for NSCLC 
during the study period, only 12 patients were excluded owing to insufficient data or advanced stage. Moreover, 
surgeons might have changed their care for patients who were in a malnourished state. However, regardless of 
nutritional status, surgeons educated all the patients planning to undergo lung resection due to lung cancer about 
nutritional support, respiration, and exercise in the same manner. Moreover, because surgical scheduling rapidly 
proceeded once the patients were diagnosed with lung cancer, there was only a short period of time to administer 
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nutritional support before surgery. Third, the observation period after surgery was relatively short to evaluate 
long-term survival outcomes. Although the mean follow-up period in this study was sufficient to evaluate PPC 
outcomes, further studies are needed to investigate long-term outcomes with respect to preoperative inflam-
matory prognostic scores. Lastly, potential factors that may affect inflammation and nutritional markers in the 
CONUT score, such as medication and nutritional support, were not included in the analysis.
conclusions
The CONUT score was found to be an independent predictor of PPCs, and it was also found to be superior to the 
PNI, GPS, and ARISCAT in terms of predicting postoperative prognosis in patients with resectable NSCLC. The 
variables used to calculate the CONUT score are readily available from laboratory data in daily clinical practice 
and preoperative evaluation, and thus the CONUT score is low cost and feasible in the clinical setting. Our 
findings provide evidence that surgeons can identify patients who are at high risk for PPCs using the CONUT 
score, and can then tailor perioperative care and ultimately improve postoperative outcomes for patients with 
NSCLC who are undergoing curative lung resection. However, further studies will be needed to determine the 
effect of nourishment before surgery in patients with a low CONUT score.
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